Latest Information Update: 03 Jul 2002
Price : $50 *
At a glance
- Originator SSP Co
- Class Antiasthmatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 03 Jul 2002 Discontinued - Phase-II for Asthma in Japan (unspecified route)
- 02 Dec 1999 SS Pharmaceuticals is now called SSP Co.
- 12 Dec 1996 Phase-II clinical trials for Asthma in Japan (Unknown route)